Ranganath Harsha A, Panella Timothy J
*Graduate School of Medicine †Department of Internal Medicine, Division of Hematology and Oncology, University of Tennessee, Knoxville, TN.
J Immunother. 2015 Jun;38(5):211. doi: 10.1097/CJI.0000000000000077.
The CTLA-4 immune checkpoint inhibitor ipilimumab improves overall survival in metastatic melanoma. Its use in organ transplant recipients has not been studied and has been reported once in the literature. We report the case of a 59-year-old liver transplant patient who was given ipilimumab after previous treatment for advanced melanoma. She did not experience organ rejection, immune-related adverse events, or evidence of tumor regression.
细胞毒性T淋巴细胞相关抗原4（CTLA-4）免疫检查点抑制剂伊匹单抗可改善转移性黑色素瘤患者的总生存期。其在器官移植受者中的应用尚未得到研究，仅在文献中有过一次报道。我们报告了一例59岁的肝移植患者，该患者在先前接受晚期黑色素瘤治疗后使用了伊匹单抗。她未出现器官排斥反应、免疫相关不良事件或肿瘤消退迹象。
